Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Neuromyelitis Optica Drug Revenue 1.4 Market Analysis by Type 1.4.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Glucocorticoids 1.4.3 Immunotherapies 1.4.4 Other 1.5 Market by Application 1.5.1 Global Neuromyelitis Optica Drug Market Share by Application: 2020 VS 2026 1.5.2 Acute attack 1.5.3 Remission Prophylactic Treatment 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Neuromyelitis Optica Drug Market Perspective (2015-2026) 2.2 Neuromyelitis Optica Drug Growth Trends by Regions 2.2.1 Neuromyelitis Optica Drug Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Neuromyelitis Optica Drug Historic Market Share by Regions (2015-2020) 2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Neuromyelitis Optica Drug Market Growth Strategy 2.3.6 Primary Interviews with Key Neuromyelitis Optica Drug Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Neuromyelitis Optica Drug Players by Market Size 3.1.1 Global Top Neuromyelitis Optica Drug Players by Revenue (2015-2020) 3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2015-2020) 3.1.3 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Neuromyelitis Optica Drug Market Concentration Ratio 3.2.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2019 3.3 Neuromyelitis Optica Drug Key Players Head office and Area Served 3.4 Key Players Neuromyelitis Optica Drug Product Solution and Service 3.5 Date of Enter into Neuromyelitis Optica Drug Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2015-2020) 4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2021-2026) 5 Neuromyelitis Optica Drug Breakdown Data by Application (2015-2026) 5.1 Global Neuromyelitis Optica Drug Market Size by Application (2015-2020) 5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Neuromyelitis Optica Drug Market Size (2015-2020) 6.2 Neuromyelitis Optica Drug Key Players in North America (2019-2020) 6.3 North America Neuromyelitis Optica Drug Market Size by Type (2015-2020) 6.4 North America Neuromyelitis Optica Drug Market Size by Application (2015-2020) 7 Europe 7.1 Europe Neuromyelitis Optica Drug Market Size (2015-2020) 7.2 Neuromyelitis Optica Drug Key Players in Europe (2019-2020) 7.3 Europe Neuromyelitis Optica Drug Market Size by Type (2015-2020) 7.4 Europe Neuromyelitis Optica Drug Market Size by Application (2015-2020) 8 China 8.1 China Neuromyelitis Optica Drug Market Size (2015-2020) 8.2 Neuromyelitis Optica Drug Key Players in China (2019-2020) 8.3 China Neuromyelitis Optica Drug Market Size by Type (2015-2020) 8.4 China Neuromyelitis Optica Drug Market Size by Application (2015-2020) 9 Japan 9.1 Japan Neuromyelitis Optica Drug Market Size (2015-2020) 9.2 Neuromyelitis Optica Drug Key Players in Japan (2019-2020) 9.3 Japan Neuromyelitis Optica Drug Market Size by Type (2015-2020) 9.4 Japan Neuromyelitis Optica Drug Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Neuromyelitis Optica Drug Market Size (2015-2020) 10.2 Neuromyelitis Optica Drug Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Neuromyelitis Optica Drug Market Size by Type (2015-2020) 10.4 Southeast Asia Neuromyelitis Optica Drug Market Size by Application (2015-2020) 11 India 11.1 India Neuromyelitis Optica Drug Market Size (2015-2020) 11.2 Neuromyelitis Optica Drug Key Players in India (2019-2020) 11.3 India Neuromyelitis Optica Drug Market Size by Type (2015-2020) 11.4 India Neuromyelitis Optica Drug Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Neuromyelitis Optica Drug Market Size (2015-2020) 12.2 Neuromyelitis Optica Drug Key Players in Central & South America (2019-2020) 12.3 Central & South America Neuromyelitis Optica Drug Market Size by Type (2015-2020) 12.4 Central & South America Neuromyelitis Optica Drug Market Size by Application (2015-2020) 13Key Players Profiles 13.1 Pfizer 13.1.1 Pfizer Company Details 13.1.2 Pfizer Business Overview and Its Total Revenue 13.1.3 Pfizer Neuromyelitis Optica Drug Introduction 13.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2015-2020)) 13.1.5 Pfizer Recent Development 13.2 Fresenius 13.2.1 Fresenius Company Details 13.2.2 Fresenius Business Overview and Its Total Revenue 13.2.3 Fresenius Neuromyelitis Optica Drug Introduction 13.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.2.5 Fresenius Recent Development 13.3 Teva 13.3.1 Teva Company Details 13.3.2 Teva Business Overview and Its Total Revenue 13.3.3 Teva Neuromyelitis Optica Drug Introduction 13.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.3.5 Teva Recent Development 13.4 Sandoz 13.4.1 Sandoz Company Details 13.4.2 Sandoz Business Overview and Its Total Revenue 13.4.3 Sandoz Neuromyelitis Optica Drug Introduction 13.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.4.5 Sandoz Recent Development 13.5 Intas 13.5.1 Intas Company Details 13.5.2 Intas Business Overview and Its Total Revenue 13.5.3 Intas Neuromyelitis Optica Drug Introduction 13.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.5.5 Intas Recent Development 13.6 Gyjtrs 13.6.1 Gyjtrs Company Details 13.6.2 Gyjtrs Business Overview and Its Total Revenue 13.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction 13.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.6.5 Gyjtrs Recent Development 13.7 NANG KUANG 13.7.1 NANG KUANG Company Details 13.7.2 NANG KUANG Business Overview and Its Total Revenue 13.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction 13.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.7.5 NANG KUANG Recent Development 13.8 Tianjin Kingyork 13.8.1 Tianjin Kingyork Company Details 13.8.2 Tianjin Kingyork Business Overview and Its Total Revenue 13.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction 13.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.8.5 Tianjin Kingyork Recent Development 13.9 Baxter 13.9.1 Baxter Company Details 13.9.2 Baxter Business Overview and Its Total Revenue 13.9.3 Baxter Neuromyelitis Optica Drug Introduction 13.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.9.5 Baxter Recent Development 13.10 CSL 13.10.1 CSL Company Details 13.10.2 CSL Business Overview and Its Total Revenue 13.10.3 CSL Neuromyelitis Optica Drug Introduction 13.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2015-2020) 13.10.5 CSL Recent Development 13.11 Grifols 10.11.1 Grifols Company Details 10.11.2 Grifols Business Overview and Its Total Revenue 10.11.3 Grifols Neuromyelitis Optica Drug Introduction 10.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2015-2020) 10.11.5 Grifols Recent Development 13.12 Octapharma 10.12.1 Octapharma Company Details 10.12.2 Octapharma Business Overview and Its Total Revenue 10.12.3 Octapharma Neuromyelitis Optica Drug Introduction 10.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2015-2020) 10.12.5 Octapharma Recent Development 13.13 CBOP 10.13.1 CBOP Company Details 10.13.2 CBOP Business Overview and Its Total Revenue 10.13.3 CBOP Neuromyelitis Optica Drug Introduction 10.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2015-2020) 10.13.5 CBOP Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Neuromyelitis Optica Drug Key Market Segments Table 2. Key Players Covered: Ranking by Neuromyelitis Optica Drug Revenue Table 3. Ranking of Global Top Neuromyelitis Optica Drug Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Glucocorticoids Table 6. Key Players of Immunotherapies Table 7. Key Players of Other Table 8. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 9. Global Neuromyelitis Optica Drug Market Size by Regions (US$ Million): 2020 VS 2026 Table 10. Global Neuromyelitis Optica Drug Market Size by Regions (2015-2020) (US$ Million) Table 11. Global Neuromyelitis Optica Drug Market Share by Regions (2015-2020) Table 12. Global Neuromyelitis Optica Drug Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 13. Global Neuromyelitis Optica Drug Market Share by Regions (2021-2026) Table 14. Market Top Trends Table 15. Key Drivers: Impact Analysis Table 16. Key Challenges Table 17. Neuromyelitis Optica Drug Market Growth Strategy Table 18. Main Points Interviewed from Key Neuromyelitis Optica Drug Players Table 19. Global Neuromyelitis Optica Drug Revenue by Players (2015-2020) (Million US$) Table 20. Global Neuromyelitis Optica Drug Market Share by Players (2015-2020) Table 21. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Drug as of 2019) Table 22. Global Neuromyelitis Optica Drug by Players Market Concentration Ratio (CR5 and HHI) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Neuromyelitis Optica Drug Product Solution and Service Table 25. Date of Enter into Neuromyelitis Optica Drug Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Neuromyelitis Optica Drug Market Size by Type (2015-2020) (Million US$) Table 28. Global Neuromyelitis Optica Drug Market Size Share by Type (2015-2020) Table 29. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021-2026) Table 30. Global Neuromyelitis Optica Drug Market Size Share by Application (2015-2020) Table 31. Global Neuromyelitis Optica Drug Market Size by Application (2015-2020) (Million US$) Table 32. Global Neuromyelitis Optica Drug Market Size Share by Application (2021-2026) Table 33. North America Key Players Neuromyelitis Optica Drug Revenue (2019-2020) (Million US$) Table 34. North America Key Players Neuromyelitis Optica Drug Market Share (2019-2020) Table 35. North America Neuromyelitis Optica Drug Market Size by Type (2015-2020) (Million US$) Table 36. North America Neuromyelitis Optica Drug Market Share by Type (2015-2020) Table 37. North America Neuromyelitis Optica Drug Market Size by Application (2015-2020) (Million US$) Table 38. North America Neuromyelitis Optica Drug Market Share by Application (2015-2020) Table 39. Europe Key Players Neuromyelitis Optica Drug Revenue (2019-2020) (Million US$) Table 40. Europe Key Players Neuromyelitis Optica Drug Market Share (2019-2020) Table 41. Europe Neuromyelitis Optica Drug Market Size by Type (2015-2020) (Million US$) Table 42. Europe Neuromyelitis Optica Drug Market Share by Type (2015-2020) Table 43. Europe Neuromyelitis Optica Drug Market Size by Application (2015-2020) (Million US$) Table 44. Europe Neuromyelitis Optica Drug Market Share by Application (2015-2020) Table 45. China Key Players Neuromyelitis Optica Drug Revenue (2019-2020) (Million US$) Table 46. China Key Players Neuromyelitis Optica Drug Market Share (2019-2020) Table 47. China Neuromyelitis Optica Drug Market Size by Type (2015-2020) (Million US$) Table 48. China Neuromyelitis Optica Drug Market Share by Type (2015-2020) Table 49. China Neuromyelitis Optica Drug Market Size by Application (2015-2020) (Million US$) Table 50. China Neuromyelitis Optica Drug Market Share by Application (2015-2020) Table 51. Japan Key Players Neuromyelitis Optica Drug Revenue (2019-2020) (Million US$) Table 52. Japan Key Players Neuromyelitis Optica Drug Market Share (2019-2020) Table 53. Japan Neuromyelitis Optica Drug Market Size by Type (2015-2020) (Million US$) Table 54. Japan Neuromyelitis Optica Drug Market Share by Type (2015-2020) Table 55. Japan Neuromyelitis Optica Drug Market Size by Application (2015-2020) (Million US$) Table 56. Japan Neuromyelitis Optica Drug Market Share by Application (2015-2020) Table 57. Southeast Asia Key Players Neuromyelitis Optica Drug Revenue (2019-2020) (Million US$) Table 58. Southeast Asia Key Players Neuromyelitis Optica Drug Market Share (2019-2020) Table 59. Southeast Asia Neuromyelitis Optica Drug Market Size by Type (2015-2020) (Million US$) Table 60. Southeast Asia Neuromyelitis Optica Drug Market Share by Type (2015-2020) Table 61. Southeast Asia Neuromyelitis Optica Drug Market Size by Application (2015-2020) (Million US$) Table 62. Southeast Asia Neuromyelitis Optica Drug Market Share by Application (2015-2020) Table 63. India Key Players Neuromyelitis Optica Drug Revenue (2019-2020) (Million US$) Table 64. India Key Players Neuromyelitis Optica Drug Market Share (2019-2020) Table 65. India Neuromyelitis Optica Drug Market Size by Type (2015-2020) (Million US$) Table 66. India Neuromyelitis Optica Drug Market Share by Type (2015-2020) Table 67. India Neuromyelitis Optica Drug Market Size by Application (2015-2020) (Million US$) Table 68. India Neuromyelitis Optica Drug Market Share by Application (2015-2020) Table 69. Central & South America Key Players Neuromyelitis Optica Drug Revenue (2019-2020) (Million US$) Table 70. Central & South America Key Players Neuromyelitis Optica Drug Market Share (2019-2020) Table 71. Central & South America Neuromyelitis Optica Drug Market Size by Type (2015-2020) (Million US$) Table 72. Central & South America Neuromyelitis Optica Drug Market Share by Type (2015-2020) Table 73. Central & South America Neuromyelitis Optica Drug Market Size by Application (2015-2020) (Million US$) Table 74. Central & South America Neuromyelitis Optica Drug Market Share by Application (2015-2020) Table 75. Pfizer Company Details Table 76. Pfizer Business Overview Table 77. Pfizer Product Table 78. Pfizer Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 79. Pfizer Recent Development Table 80. Fresenius Company Details Table 81. Fresenius Business Overview Table 82. Fresenius Product Table 83. Fresenius Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 84. Fresenius Recent Development Table 85. Teva Company Details Table 86. Teva Business Overview Table 87. Teva Product Table 88. Teva Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 89. Teva Recent Development Table 90. Sandoz Company Details Table 91. Sandoz Business Overview Table 92. Sandoz Product Table 93. Sandoz Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 94. Sandoz Recent Development Table 95. Intas Company Details Table 96. Intas Business Overview Table 97. Intas Product Table 98. Intas Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 99. Intas Recent Development Table 100. Gyjtrs Company Details Table 101. Gyjtrs Business Overview Table 102. Gyjtrs Product Table 103. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 104. Gyjtrs Recent Development Table 105. NANG KUANG Company Details Table 106. NANG KUANG Business Overview Table 107. NANG KUANG Product Table 108. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 109. NANG KUANG Recent Development Table 110. Tianjin Kingyork Business Overview Table 111. Tianjin Kingyork Product Table 112. Tianjin Kingyork Company Details Table 113. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 114. Tianjin Kingyork Recent Development Table 115. Baxter Company Details Table 116. Baxter Business Overview Table 117. Baxter Product Table 118. Baxter Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 119. Baxter Recent Development Table 120. CSL Company Details Table 121. CSL Business Overview Table 122. CSL Product Table 123. CSL Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 124. CSL Recent Development Table 125. Grifols Company Details Table 126. Grifols Business Overview Table 127. Grifols Product Table 128. Grifols Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 129. Grifols Recent Development Table 130. Octapharma Company Details Table 131. Octapharma Business Overview Table 132. Octapharma Product Table 133. Octapharma Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 134. Octapharma Recent Development Table 135. CBOP Company Details Table 136. CBOP Business Overview Table 137. CBOP Product Table 138. CBOP Revenue in Neuromyelitis Optica Drug Business (2015-2020) (Million US$) Table 139. CBOP Recent Development Table 140. Research Programs/Design for This Report Table 141. Key Data Information from Secondary Sources Table 142. Key Data Information from Primary Sources List of Figures Figure 1. Global Neuromyelitis Optica Drug Market Share by Type: 2020 VS 2026 Figure 2. Glucocorticoids Features Figure 3. Immunotherapies Features Figure 4. Other Features Figure 5. Global Neuromyelitis Optica Drug Market Share by Application: 2020 VS 2026 Figure 6. Acute attack Case Studies Figure 7. Remission Prophylactic Treatment Case Studies Figure 8. Neuromyelitis Optica Drug Report Years Considered Figure 9. Global Neuromyelitis Optica Drug Market Size YoY Growth 2015-2026 (US$ Million) Figure 10. Global Neuromyelitis Optica Drug Market Share by Regions: 2020 VS 2026 Figure 11. Global Neuromyelitis Optica Drug Market Share by Regions (2021-2026) Figure 12. Porter's Five Forces Analysis Figure 13. Global Neuromyelitis Optica Drug Market Share by Players in 2019 Figure 14. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Drug as of 2019 Figure 15. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2019 Figure 16. North America Neuromyelitis Optica Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 17. Europe Neuromyelitis Optica Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 18. China Neuromyelitis Optica Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Japan Neuromyelitis Optica Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 20. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 21. India Neuromyelitis Optica Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Central & South America Neuromyelitis Optica Drug Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 24. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 25. Fresenius Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 27. Teva Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 29. Sandoz Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 31. Intas Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 33. Gyjtrs Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 35. NANG KUANG Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 37. Tianjin Kingyork Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 39. Baxter Total Revenue (US$ Million): 2019 Compared with 2018 Figure 40. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 41. CSL Total Revenue (US$ Million): 2019 Compared with 2018 Figure 42. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 43. Grifols Total Revenue (US$ Million): 2019 Compared with 2018 Figure 44. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 45. Octapharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 46. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 47. CBOP Total Revenue (US$ Million): 2019 Compared with 2018 Figure 48. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2015-2020) Figure 49. Bottom-up and Top-down Approaches for This Report Figure 50. Data Triangulation Figure 51. Key Executives Interviewed

Pfizer Fresenius Teva Sandoz Intas Gyjtrs NANG KUANG Tianjin Kingyork Baxter CSL Grifols Octapharma CBOP